Novavax, Inc. has announced preclinical data for its H5N1 avian pandemic influenza vaccine candidate, which demonstrated immunogenicity against currently circulating variants. The study, published in Nature Communications, showed that the vaccine, which utilizes Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses in nonhuman primates following either a single or two-dose administration via intranasal or intramuscular routes. The results indicated that even a single dose could potentially provide protective immunity, especially in individuals previously exposed to seasonal influenza. These findings suggest that Novavax's vaccine could play a significant role in pandemic emergency preparedness efforts. The company is seeking funding, partnership, and licensing opportunities to advance its H5N1 vaccine candidate.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。